A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Feb 8, 2023

Keywords

ClinConnect Summary

This clinical trial is looking into the use of special medications called redifferentiating agents as a standard treatment for patients with a type of thyroid cancer that does not respond well to radioactive iodine treatment. The goal is to gather information on how these medications can help improve treatment options for people with refractory thyroid cancer. This study is currently recruiting participants who are 18 years or older and have been diagnosed with this specific type of thyroid cancer.

To be eligible for this trial, patients should either be starting redifferentiation medications before their planned radioactive iodine treatment or have previously received these medications during their regular care. Participants will be asked to provide information about their treatment experiences and health during the study. It’s important to note that this trial does not include patients who are currently enrolled in other clinical trials for redifferentiation agents. If you or someone you know is facing this type of thyroid cancer, this study may offer a chance to explore new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥ 18 years old at time of consent
• Inclusion Criteria:
• • Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.
• • Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care.
• • Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration.
• • Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.
• Exclusion Criteria:
• • RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.